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Activation of peripheral blood cells (PBL)  ~ of cancer patients with autologous 
tumor cells (1) or in conventional mixed lymphocyte culture (MLC) with alloge- 
neic PBL of a single donor (2, 3), a pool of 10-20 unrelated individuals (3, 4) or 
with an Epstein-Barr Virus (EBV) transformed lymphoblastoid B cell line (5) has 
been shown to result in the induction  of cytotoxicity against autologous tumor 
cells.  These  studies  have  indicated  that  the  PBL  of cancer  patients  contain 
precursors of cells cytotoxic for autologous tumor cells.  However, the  hetero- 
geneity of bulk T  cell cultures, especially of those activated in MLC, prevents a 
meaningful  analysis of the  effector- and  target  cell antigens  involved  in  auto- 
tumor cell cytotoxicity. Recently we demonstrated that cloned lines of cytotoxic 
T  lymphocytes (CTL) that lysed autologous, short-term cultured melanoma cells, 
could be established in MLC and mixed lymphocyte tumor cell culture (MLTC) 
(5).  Both T4+ and T8+ CTL clones were isolated and were shown to preferen- 
tially lyse melanoma cells. This cytotoxicity was not HLA-restricted. The reactiv- 
ity of the CTL clones was found to differ from that of CTL clones specific for 
HLA antigens,  since the reactivity was not blocked with monocional antibodies 
against HLA antigens.  Moreover, antibodies against T3, T4, and T8 that block 
the  activity  of T4+  and  T8+  CTL  clones  against  class  II  and  class  I  MHC 
antigens  (6,  7),  were not able to inhibit  the auto-tumor  cell reactivity.  Similar 
CTL clones with a restricted cytotoxic pattern lysing only autologous melanoma 
cells have been described (8). 
In  our  previous  studies,  short-term  cultured  melanoma  cells  were  used  as 
target cells. Tissue culture of tumor cells may result in an increased susceptibility 
to nonspecific cytotoxic effects. We could, however demonstrate that  the mela- 
noma target cells used were not susceptible to T  cell bulk cultures having a high 
activated killer  (AK) cell activity against  the  myeloid/erythroid human  natural 
killer (NK)- and AK-sensitive target cell K562.  However, to avoid any interfer- 
ences of tissue culture of the target cells we investigated whether similar  CTL 
clones could  also  be  generated  against  fresh,  noncultured  autologous  human 
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lymphoma  cells.  In  this  paper  it  is  demonstrated  that  cloned CTL  lines  with 
strong  cytotoxic  activity  against  autologous  fresh  lymphoma  cells  could  be 
isolated from PBL, obtained from a  B cell lymphoma patient, and activated by 
cocultivation with autologous lymphoma cells. Analysis of the specificity of the 
CTL clones obtained,  indicated  that  in  addition  to the  autologous lymphoma 
cells, allogeneic fresh lymphoma target cells were also lysed, whereas most other 
target cells of different origin were not killed.  Furthermore it is demonstrated 
that LFA-1, but neither T3 nor T4, plays a role in the activity of the B iymphoma 
specific CTL clones. 
Materials and Methods 
Media and Reagents.  All experiments and cell cultures were carried out in serum-free 
medium as described (9). The composition of serum-free medium was based on Iscove's 
modification of Dulbecco's modified Eagle's medium, referred to as  Iscove's, and was 
reconstituted according to the manufacturer's directions (Gibco Biocult, Glasgow, Scot- 
land) with distilled, deionized water to which 3.024 g/l NaHCOs (Merck, Darmstadt, W. 
Germany) was added. The medium was supplemented with ethanolamine (2 x  10  -5 M, 
Merck), bovine serum albumin (BSA,  0.25%), transferrin (35/~g/ml), insulin (5 ug/ml), 
linoleic acid, oleic acid, and palmitic acid (1 t~g/ml), purchased from Sigma Chemical Co., 
St.  Louis, MO. Penicillin and streptomycin (Gibco) were added to a final concentration 
of 100 U/ml). Stock solutions of transferrin (20 mg/ml) and insulin (2.5 mg/ml) were 
prepared in phosphate-buffered saline (PBS) and 0.01 N HCI, respectively. The saturated 
and unsaturated fatty acids were first dissolved in ethanol (Merck) (5  mg/ml) and then 
diluted to the appropriate concentration in Iscove's. 
B Lymphoma Cells.  The autologous B lymphoma cells that were used as stimulator and 
target cells in this study were obtained from pleural effusions and referred to as MPL. 
The other allogeneic  B  lymphoma cells  were collected from spleen  extirpations of B 
lymphoma patients. 
Viable tumor cells were separated from nonviable cells and erythrocytes by centrifuga- 
tion (15 min, 800 g) over Ficoll/Hypaque. After two washings  at 4°C with PBS supple- 
mented with 0.2% BSA, the cells were resuspended in RPMI-1640 (Grand Island Biolog- 
ical Co., Grand Island, NY), containing 1% BSA, and an equal volume of ice-cold RPMI- 
1640 containing 1% BSA and 20% dimethyl sulfoxide (DMSO) was added dropwise over 
a  period  of 3-5  min.  The  cells  were  frozen  in  a  cooling  chamber  according  to  a 
temperature-controlled program and stored in liquid nitrogen. After thawing, the cells 
were used as target cells for the CTL clones. If necessary, dead cells were removed by 
centrifugation over Ficoll/Hypaque. 
Description of the B  Lymphomas.  All  the  B  lymphomas  used  in  this  study  were  of 
advanced stage IV. The further characteristics of the B lymphomas were as follows: 
MPL: centrocytic/centroblastic, poorly differentiated, diffuse; surface markers  IgM, 
IgD, kappa.  LIV: centrocytic/centroblastic, well-differentiated, diffuse; surface markers 
IgM,  kappa.  KOS:  centrocytic, well-differentiated, diffuse; surface markers IgM,  IgD, 
kappa. TOP: centrocytic, poorly differentiated, diffuse; surface markers IgM, IgD, IgG, 
kappa. STS: centrocytic/centroblastic,  poorly differentiated, diffuse; surface markers IgM, 
IgD, kappa. KOR: centrocytic/centroblastic, poorly differentiated, diffuse; surface mark- 
ers IgG, lambda.  PLN: centrocytic/centroblastic, poorly differentiated, diffuse; surface 
markers IgM,  IgD,  IgG,  lambda.  POS: centrocytic/centroblastic, poorly differentiated, 
nodular; surface markers IgM, lambda. 
PBL.  Mononuclear leukocytes from a  66-year old female patient with centrocytic/ 
centroblastic B cell lymphoma were obtained by centrifugation over a  Ficotl/Hypaque 
mixture and were enriched for T cells by rosetting with sheep erythrocyte SE as described 
previously (9). The HLA phenotype of this patient was HLA-A1,2;B8,w62;Cw3;DRw3,6. 
Mixed Leukocyte Tumor Cell Culture (MLTC).  M LTC was carried out in Iscove's medium 
in 2-ml tissue culture plates (Linbro, no. 74-033-05, Linbro, Hamden, CT). 106 responder YSSEL ET  AL.  241 
T  cells were stimulated with 106 irradiated (3,000 rad) MPL. On day 10 secondary MLC 
was carried out, in which the remaining PBL were restimulated with irradiated MPL. 4 d 
later the PBL were collected, washed with serum-free medium, and cloned by limiting 
dilution. 
Cloning  by Limiting  Dilution.  Cloning by limiting dilution  was carried out in  serum- 
free  medium  as  described  previously (9).  After  secondary  stimulation  the  PBL  were 
collected, washed, and seeded in fiat-bottomed microtiter wells  (Costar, no.  3596)  at a 
concentration of 1 cell/well in the presence of a feeder mixture consisting of 103 allogeneic 
PBL,  104 autologous lymphoma cells (both irradiated, 3,000 rad), and 0.1  ug/ml PHA or 
2% (voi/vol) of an IL-2-containing supernatant (9) in a final volume of 0.1  ml. After 10- 
14 d culturing in a humidified atmosphere of 5% CO2 at 37 °C proliferating clones were 
transferred to 1-ml wells (Linbro, no. 74-033-05) and weekly supplied with the feeder cell 
mixture described above. 
Monoclonal Antibodies.  Monoclonal antibody OKT4A, which reacts with a subset of T 
cells including the helper/inducer T  cells (10), was obtained from Ortho Pharmaceutical 
Corp., Raritan, NJ. The SPV monoclonal antibodies used in this study were produced by 
hybridomas that were obtained by fusing SP 2/0 myeloma cells (11) with spleen cells from 
mice immunized with the T4+ clone HG-38 or with the TS+ clone HG-31, and were 
selected according to their capacity to inhibit the cytotoxic reactivity of these clones (7, 
12). SPV-T3a, SPV-T3b, SPV-T3c, and SPV-T8 have all the characteristics of antibody 
specific for the T3 molecular complex (OKT3, Leu-4) (13,  14) and T8 (OKT8, Leu-2a) 
(15,  16),  respectively.  The  monoclonal  antibodies  SPV-L1  and  SPV-L5  inhibited  the 
cytotoxic reaction  of T8+ and T4+  CTL clones specific for class  I  and class  II MHC 
products. They precipitated a complex of two polypeptides with a mol wt of 95,000 and 
160,000,  suggesting that SPV-L1  and SPV-L5 recognize a  human  leukocyte function- 
associated antigen  (LFA-1) (17).  The  monoclonal antibody SPV-L3 precipitated a  bio- 
molecular complex with a  mol wt of 28,000  and 34,000  and was shown to recognize a 
determinant on H LA-DC (12).  The monoclonal antibody Mas 015 (W6/32) reacting with 
a  framework determinant on HLA-A, B, and C antigens (18) was purchased from Sera 
Lab Ltd., Sussex, England. The monoclonal antibody Q 5/13, recognizing a monomorphic 
determinant on the HLA-DR chain (19), was kindly provided by Dr. S. Ferrone from the 
Department of Pathology, College of Physicians and Surgeons, Columbia University, New 
York. 
Assays  for Determination of Cytotoxic Activity.  Cytotoxic activity of the CTL was measured 
in a 5~Cr release assay, which was carried out in round-bottomed microtiter plates (Linbro, 
Titertek) in a volume of 200 tzl. 104 5~Cr-labeled lymphoma target cells (or 103 lymphoid 
nonlymphoma cells) were incubated with various numbers of CTL effector cells in Iscove's 
medium supplemented with 0.25%  BSA. The plates were centrifuged for 5 min at 50 g 
and  incubated  during  4-8  h  at  37°C  in  an atmosphere of 5%  CO2.  Then  100  ul  of 
supernatant were collected from each well and counted in a gamma counter (Beckman). 
All tests were carried out in triplicate. The percentage-specific 5~Cr release was calculated 
according to the formula: 
Release in sample -  Release in medium/Release in  Triton X-100 
-  Release in medium x  100%. 
Inhibition  of Cytotoxic Activity of the CTL Clones with Monoclonal Antibodies.  Inhibition 
of cytotoxicity with monoclonal antibodies was determined in a cytotoxic inhibition assay. 
1033tCr-labeled target cells were incubated in the absence or presence of 10 #1 appropri- 
ately diluted monoclonal antibody for 20 min at room temperature. Then 20 #1 effector 
cells were added.  The mixture was centrifuged at 50 g during 5 min and incubated as 
described above. After the incubation period  150 ttl ice-cold medium were added. The 
plates were centrifuged at 50 g for 5 min after which  100 tzl was harvested and counted. 
The percentage inhibition was calculated as follows: 
100 -  % Lysis in the presence of monoclonal antibody/% Lysis in the absence of 
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Phenotyping with Monoclonal Antibodies.  Phenotyping of the CTL clones was carried 
out  by indirect  immunofluorescence as  follows:  5  ×  105  CTL  were  washed  with  PBS 
supplemented with 0.2% BSA and 0.1% NaN3 and incubated with 40 #l of an appropriate 
dilution of the monoclonal antibodies OKT4 (Ortho) or SPV-T8 for 30 min at 4°C. The 
cells  were  washed  three  times  in  a  refrigerated  centrifuge  and  incubated  with  FITC- 
labeled goat anti-mouse Ig (Nordic, Tilburg, The Netherlands) for 30 min at 4°C. Finally 
the cells were washed three times and analyzed using a FACS IV. 
Modulation of the T3 Determinant.  Antigen modulation of the T3  complex from the 
CTL clones was induced by incubation with anti,SPV-T3b monoclonal antibody for 24 h 
at 37°C. The CTL cells were cultured in Iscove s at a concentration of 4  ×  106 cells/ml 
with a final dilution of anti-SPV-T3b monoclonal antibody of 1:100 in the presence of 2 
×  106/ml  MPL  cells.  CTL  clones,  incubated  with  MPL cells  only,  served  as  negative 
control. After modulation the cells were centrifuged over Ficoll/Hypaque to remove dead 
cells,  collected,  and  washed  extensively.  Control  and  SPV-T3b  modulated  cells  were 
analyzed for reactivity with anti-SPV-T3b  monoclonal antibody by measuring indirect 
fluorescence on a FACS IV cell sorter using FITC-conjugated goat anti-mouse Ig (Nordic, 
Tilburg, The Netherlands). Untreated cells incubated with anti-SPV-T3b and PBS served 
as positive and negative control, respectively. 
Results 
Generation of Cytotoxic Activity in Primary and Secondary MLTC.  PBL from a  B 
cell lymphoma patient were enriched for T  cells by rosetting with SRBC and the 
E+ cells were stimulated  in primary MLTC  and after another  10 d  in secondary 
MLTC  by  cocultivation  with  MPL  cells.  As  is  shown  in  Table  I,  the  primary 
stimulated T  cells were not cytotoxic for the MPL cells, but restimulation resulted 
in  the appearance  of CTL  activity  indicating  that  the  culture  contained  clones 
cytotoxic for MPL cells. 
Isolation and Screening of Cytotoxic Clones with Auto-tumor Reactivity.  7  d  after 
secondary stimulation  the  remaining  cells were  restimulated  in  the presence  of 
allogeneic  PBL,  MPL  cells,  and  PHA  and  were  cloned  7  d  later  by  limiting 
dilution.  In only 6/10 wells in which  1,000 cells/well were seeded,  growing cells 
TABLE  I 
PBL, Not Cytotoxic  for Autologous MPL Cells After Primary MLTC, Show 
Lytic Activity Against MPL After Secondary MLTC and After Cloning by 
Limiting Dilution 
Effector cells 
Percentage of specific lysis 
Effector/target cell ratio 
5:1  20:1  40:1 
A: Primary MLTC*  2 
B:  Secondary MLTC*  12 
C: Cloning of B on 1,000 cells/well  25 
D: Cloning of C on 0.5 cells/well 
MWS-14  30 
E:  Subcloning of MWS-14 on 0.5 cells/well 
MWS-14-340  32 
% 
2  3 
20  42 





* Effector cells were E  ÷ cells tested on day 7 after primary MLTC. 
* Tested on day 4 after onset secondary MLTC. 
Subcloning  of MWS-14 yielded  34  subclones  with  comparable 
against autologous MPL cells. 
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were observed. Cells from one of these six wells were shown to be cytotoxic for 
the  MPL  cells.  These  cytotoxic cells were seeded at a  concentration  of ~0.5 
cells/well in the presence of the feeder cell mixture.  Only 4/10 wells contained 
proliferating cells.  From  these four wells one clone (MWS-14) showed a  stable 
lytic activity against the autologous target cells. 
Phenotyping revealed that clone MWS-14 expressed the T3+, T4+, and T8- 
surface markers.  To exclude the possibility that this clone was a  mixture of two 
clones, it was subcloned at a concentration  of ~0.5 cells/well and two subciones 
were selected for further investigation. 
Specificity of the CTL Clones.  The specificity of the CTL clone MWS-14 and 
the  subclones  MWS-14-30  and  MWS-14-34  was  determined  by  testing  the 
cytotoxic activity against a panel of cells originating from various normal tumor 
tissues,  including  a  large  number  of target  cells which  are  known  to  be very 
susceptible for NK-cell killing.  Table II shows that seven of seven B lymphoma 
cell  types were  lysed by the  CTL  clones,  indicating  that  all  B  lymphoma  cell 
types tested  express  determinants  recognized  by  MWS-14.  In  contrast  to  the 
general  activity against  B  lymphoma  cells,  MWS-14-30  and  MWS-14-34  were 
cytotoxic for only 3 of 23 target cells, respectively 2 of 23 normal- and malignant 
lymphoid and  nonlymphoid  target  cells (Table  III).  Importantly,  the  two sub- 
clones failed to lyse an EBV-transformed B cell line derived from PBL of one of 
the B lymphoma patients (KOS) whose B lymphoma cells were killed (Table II). 
The  EBV-transformed  B  cell  line  KOS  had  the  same  HLA phenotype as  the 
KOS B lymphoma cells, but did not react with a  monoclonal antibody directed 
against the idiotype of the Ig present on KOS B lymphoma cells (E. Rankin and 
A. Hekman, submitted for publication).  In addition the subciones failed to lyse 
PHA-activated PBL from any of the B  lymphoma patients  (Table III).  It is of 
interest  to  note  that  although  both  subclones,  MWS-14-30  and  MWS-14-34, 
killed  all  lymphoma  cells  to  the  same  extent,  the  subclones differed  in  their 
killing activity against HSB and T24. The reason for this difference is unknown, 
but it may be due to the  fact that  in  some instances  CTL clones may acquire 
nonspecific cytotoxic activities that can be measured against particular  sensitive 
target cells, as has been described for allospecific mouse CTL clones (20). Taken 
together the data presented  in Tables II and  III  indicate that  the CTL clones 
MWS-14-30  and  MWS-14-34  recognize  antigens  preferentially  expressed  on 
malignant  B lymphoma cells. 
Fresh MPL Cells Are Resistant to Lysis by Allogeneic PBL Containing NK/AK Cells 
and by CTL Clones Directed at HLA Specificities Not Present on the MPL Cells.  It 
has been described that lysis of human tumor cells in T cell-mediated cytotoxicity 
can be contributed to "natural  killer" (NK) or "activated killer" (AK) activity in 
which specific antigen recognition is not involved (21, 22). This type of cytotoxic 
reaction,  mediated  by activated  T  cells,  is  defined  by the  lysis  of the  human 
erythroid/myeloid cell line K562 (23, 24).  PBL stimulated with PHA or alloge- 
neic EBV-transformed B cells are highly cytotoxic for K562 (reference 25; Table 
IV) but it is also shown that such activated T  cells fail to iyse the MPL cells. It is 
furthermore shown in Table IV that a cloned T  cell line (POS-41) isolated from 
PBL  stimulated  with  PHA,  which  was  highly  cytotoxic  for  K562,  was  not 
cytotoxic for MPL cells. The MPL cells express HLA-A2 and HLA-DC-1 and as 244  CYTOTOXIC  T  LYMPHOCYTE  CLONES  AGAINST  HUMAN  LYMPHOMA 
TABLE  II 
Cytotoxic Pattern of Clone MWS-14 and Subclones MWS-14-30  and MWS-14-34  Tested 
Against a Panel of Human Normal and Nonlymphoma Cells 
Target cells 
Percentage of specific 5tCr-release* 
CTL clone* 
MWS-14  MWS-14-30  MWS-14-34 
HL-60 (promyelocytic leukemia) 
U937 (histiocytic leukemia) 
K562 (erythroid/myeloid leukemia) 
KG-1 (myelocytic leukemia) 
DAUDI (Burkitt's lymphoma) 
HPB-ALL (T leukemia) 
CEM (T leukemia) 
JY (EBV-transformed B cell line) 
KOS-EBV 0 (EBV-transformed B cell line) 
CRIS (EBV-transformed B cell line) 
HHK (EBV-transformed B cell line) 
APD (EBV-transformed B cell line) 
AVL (EBV-transformed B cell line) 
LAZ 475 (EBV-transformed B cell line) 
E-14-17 (EBV-transformed B cell line) 
A 549 CI 8 (broncho alveolar carcinoma) 
MCF-7 (mamma carcinoma) 
CAMA (mamma carcinoma) 





MPL (autologous B lymphoma as control) 
% 
3  2  2 
5  6  7 
4  9  9 
0  1  2 
6  8  8 
21  31  24 
18  16  26 
7  2  2 
10  12  12 
14  12  11 
8  7  0 
4  6  2 
2  1  0 
3  1  1 
6  7  1 
2  1  1 
5  5  4 
4  3  1 
25  28  16 
2  1  1 
7  11  6 
2  0  1 
1  0  0 
42  45  48 
* Cytotoxicity was also measured at E/T ratios of 10:1 and 20:1. The reaction pattern was the same 
as the one obtained at  E/T  ratio of 5:1.  % specific  ~Cr-release <15%  at any E/T  ratio were 
considered as negative, since the average percentage of lysis obtained with different (control) CTL 
clones, augmented with two times the SD never exceeded 15% lysis. 
* E/T ratio 5: I. 
KOS-EBV is the EBV-transformed B cell line from B lymphoma patient KOS (see Table III). 
expected, they were killed by the T8+  HLA-A2  specific CTL  clone JR-2-16 and 
the T4+  HLA-DC-I  specific CTL  clone JR-2-19  (6, 7). 
In  contrast,  CTL  clones  directed  at  HLA  determinants  not  present  on  the 
lymphoma  cells (HG-31,  LIV-8, directed against HLA-B7,  and HG-38,  directed 
against an  unknown  HLA-DC  product)  failed to kill both  MPL  cells and  K562 
cells. Since the  MPL  cells are not susceptible to nonspecific lysis and were only 
lysed by allospecific CTL  clones recognizing MHC  determinants  present on the 
lymphoma cells, it is concluded that the anti-lymphoma activity of the CTL  clone 
MWS-14 is antigen specific. 
MHC  Antigens  Are  Not  Involved  in  the  Cytotoxic  Reactivity  of the  CTL  Clones 
Against the MPL Cells.  The  activity of the  CTL  clones against allogeneic lym- 
phoma  cells already indicated that the activity of clone MWS-14 is not restricted 
by HLA  products.  It cannot  be excluded,  however,  that  clone  MWS-14  recog- YSSEL ET AL.  245 
TABLE II1 
Cytotoxic Pattern of CTL Clone MWS-14 and Subclones MWS-14-30  and MWS-14-34  Tested 
Against a Panel of Human Lymphoma Cells and Normal T CeUs  from the Same Donors 
Target cells* 
HLA phenotype  Percentage of specific  5~Cr release 
CTL clone* 
A  B  C  DR  MWS-14 MWS-14-30  MWS-14-34 
% 
M  PL lymphoma  1,2  8,w62  w3 ,w7  w3 ,w6  46  46  41 
T cells  3  2  5 
LIV lymphoma  2,w31  w44,w60  w3  w2,--  44  49  37 
T cells  7  4  5 
KOS lymphoma  1,11  12,17  w5,w7  w2,w4  45  48  53 
T cells  3  3  4 
TOP lymphoma  3,w33  17,w35  w3,w6 wl,w6  30  24  31 
T cells  8  5  10 
STS lymphoma  2,3  13,w35  w4  w2,w7  36  38  40 
T cells  2  1  5 
KOR lyrnphoma  2,w24  w44,w38  --  w2,w7  27  25  29 
T cells  6  6  9 
PLN lymphoma  NT  g  42  46  48 
T cells  8  3  4 
POS lymphoma  NT  39  42  36 
T cells  2  2  6 
* As T cell were used PHA blasts of E  + cells. 
* E/T cell ratio 10:1. 
0 Not tested. 
nizes putative  "alien"  HLA antigens,  which  may be expressed on malignant  B 
lymphoma cells. To further investigate the involvement of HLA antigens in the 
killing activity of MWS-14 against MPL cells, blocking studies were carried out 
with  anti-class  I  MHC  and  anti-class  II  MHC  antibodies  which  were  shown 
previously to block very efficiently the activity of allospecific CTL clones (6, 7). 
Table V  shows that the activity of JR-2-16  (HLA-A2 specific) against  MPL was 
also blocked effectively by W6/32  (18).  Furthermore, the lysis of MPL by the 
CTL clones JR-2-10  directed at  HLA-DRw6,  and JR-2-19,  directed at  HLA- 
DC-1, was blocked by the monomorphic antibodies Q  5/13 (anti-HLA-DR) (19) 
and SPV-L3  (anti-HLA-DC/DS) (12),  respectively. These four antibodies  were 
all  found to react with  the  MPL  cells (not shown).  In  contrast,  the  activity of 
MWS-14 and MWS-14-34 against MPL was not blocked by any of the anti-class 
I  MHC  or anti-class  II  MHC  specific antibodies.  The monocionaI anti-class  I 
and  anti-class  II  MHC  antibodies also  failed  to block the activity of MWS-14 
against  allogeneic  B  lymphoma  cells  (not  shown).  Taken  together  these  data 
indicate that the cytotoxic activity of MWS-14 against autologous and allogeneic 
B  lymphoma  cells  is  not  directed  against  "alien"  HLA  antigens,  nor  MHC 
restricted. 
T  Cell Differentiation  Antigens Are Not Involved  in  the  Cytotoxic  Reaction  of the 
CTL Clones.  Blocking studies with monoclonal antibodies directed against T3, 
T4, and T8 have shown that these antigens are involved in the cytotoxic activity 
of T4+ CTL clones directed at class II (26, 27) and of T8+ CTL clones directed 246  CYTOTOXIC  T  LYMPHOCYTE  CLONES  AGAINST  HUMAN  LYMPHOMA 
TABLE  IV 
Fresh MPL Cells Are Resistant to Lysis by AUogeneic PBL Containing 
NK/AK Cells and by CTL Clones Directed at HLA Specificities  Not 
Present on MPL Cells 
Effector cells* 
Percentage of specific 5JCr re- 
lease target cells 
MPL  K562 
Bulk T  cell (MLC)* 
E/T cell ratio  40:1  11  92 
20:1  9  85 
10:1  7  86 
5:1  4  83 
Bulk T  cell (PHA)  0 
E/T cell ratio  40:1  12  53 
20:1  7  35 
10:1  2  19 
5:1  3  10 
POS-41  7  49 
JR-2-16  59  6 
JR-2-19  25  7 
HG-31  3  6 
LIV-8  6  2 
HG-38  8  3 
MWS-14  44  4 
MWS-14-34  47  9 
* E/T cell ratio of the CTL clones 10:1. 
* Tested 7 d after onset MLC. 
Tested 4 d after PHA stimulation. 
TABLE  V 
MHC Antigens Are Not Involved in the Cytotoxic  Reaction of CTL 
Clone MWS-14 Against MPL Cells and Allogeneic Lymphoma Cells 
CTL clone*  Target cell  Lysis 
Percentage of specific inhibi- 
tion in the presence of  t 
W6/32  Q  5/13  SPV-L3 
%  % 
JR-2-16  MPL  53  80  l  3 
LIV  40  69  3  4 
JR-2-10  MPL  32  0  50  0 
TOP  28  2  55  0 
JR-2-19  MPL  25  0  0  90 
KOS  30  0  0  70 
MWS-14  MPL  41  1  2  5 
POS  30  10  3  10 
LIV  34  0  1  0 
KOS  38  1  0  0 
* E/T ratio 10:1. 
* Dilution of 1  : 100 ascites fluid. YSSEL ET  AL.  247 
at class I  MHC antigens (6,  7).  As expected,  OKT4A and SPV-T8  are able to 
block the activity of T4+ CTL clone JR-2-19 and the T8+ clone JR-2-16 against 
the  MPL  cells (Table  VI).  In  addition anti-T3  reagents (SPV-T3a,  SPV-T3b) 
were able to block efficiently the cytotoxic activity of  JR-2-16 and JR-2-19 (Table 
VI). In contrast, none of the anti-T4 or anti-T3 reagents inhibited the activity 
of the T3+ T4+ clone MWS-14 against the MPL. 
Anti-T3, however, not only blocks but also induces cytotoxicity and therefore 
blocking of the cytotoxic reaction can be masked by a high induction of cytotox- 
icity (H. Spits, manuscript submitted for publication). Therefore we decided to 
modulate the  T3  complex  from  the effector cells with anti-T3  antibody (28). 
Fig. 1 a illustrates that after incubation of clones MWS-14 and JR-2-19 with SPV- 
T3b, >90%  of the T3 was removed and the cytotoxic activity of the modulated 
JR-2-19 against the MPL cells was abolished (Fig. 1 b). Addition of 10 #g/ml Con 
A restored the cytotoxic activity, indicating that the loss of function was not due 
to an aspecific inactivation of the CTL clone. In contrast, the cytotoxic activity 
of clone  MWS-14  against  the  autologous  lymphoma cells  was  not affected by 
modulation of the T3  complex (Fig.  1 b).  Furthermore, addition of Con A  did 
not enhance the cytotoxic activity of this CTL clone.  These results confirmed 
the inhibition experiments with anti-T3 and indicated that T3  is not associated 
with the cytotoxicity mediated by MWS-14. 
Human  LFA  Is  Involved  in  the  Cytotoxic  Reaction  of MWS-14.  Monoclonal 
antibodies  directed  at  the  function-associated  antigen  LFA-1  block  antigen- 
specific CTL-mediated killing (12,  17,  29) as well as NK (12,  29),  AK (12),  K 
cell activity (F. Miedema et al., submitted for publication) and lectin-dependent 
cytotoxicity (12).  Table V  demonstrates that two monoclonal antibodies,  SPV- 
L1  and  SPV-L5,  which  recognize  LFA-1  (12),  block  the  activity of MWS-14 
against MPL cells, indicating that LFA-1 is involved in this cytotoxic reaction. 
Discussion 
In this paper a novel type of T3-independent, antigen-specific anti-lymphoma 
cytotoxicity mediated  by  a  T3+  T4+  T8-  CTL  clone  directed  against  fresh 
TABLE  VI 
T Cell Differentiation  Antigens Are Not Involved in the Cytotoxic Reaction of CTL 
Clone MWS-14 and Subclones MWS-14-30 and MWS-14-34 Against MPL Cells 
CTL clone*  Lysis 
Percentage of specific inhibition in the presence of * 
SPV-T3b  OKT4A  SPV-T8  SPV-L1 SPV-L5 
% 
JR-2-16  40  37  3  51  65  55 
JR-2-10  45  70  40  5  50  42 
JR-2-19  25  72  50  6  62  85 
MWS- 14  42  0  5  NT  i  40  35 
MWS-14-30  45  3  2  NT  50  34 
MWS- 14-34  46  3  1  NT  45  31 
* E/T cell ratio 10:1. 
* Dilution of 1:100 of SPV-T3b, OKT4A, SPV-T8, and 1:400 of SPV-LI and SPV- 
L5. 
! Not tested. 248  CYTOTOXIC  T  LYMPHOCYTE  CLONES  AGAINST  HUMAN  LYMPHOMA 
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5O 
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MWS  14 
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modulation  with  SPV  T3b  *  CONA 
JR  ~  2  19 
FIGURE  1.  Modulation with SPV-T3b. (a) Modulation of T3 by SPV-T3b treatment, MWS- 
14 cells were incubated with the monoclonal antibody SPV-T3b (final dilution ]:100) for 24 
b  at  37°C  and subsequently washed several times.  Surface phenotype  was  determined by 
means of indirect immunofluorescence before modulation (light areas) and after modulation 
(dark areas). C, C mod.: immunofluorescence with PBS; SPV-T3b, SPV-T3b rood.: immunoflu- 
orescence with SPV-T3b. JR-2-19  showed an  identical pattern  of immunofluorescence. (b) 
Specific cytotoxicity after modulation by SPV-T3b treatment. MWS-14 and JR-2-19 cells were 
tested against MPL cells before modulation (light areas) and after modulation (dark areas). E/ 
T  cell ratio 10:1. Con A  was used at a  final concentration of 10 ~tg/ml, and added with the 
target cells at initiation of the cytotoxicity assay.  This concentration had no effect on  the 
spontaneous release of StCr. 
autologous B iymphoma cells (MPL cells) is described. Panel studies with various 
cells  from  normal  and  malignant  tissues,  including  many cells  that  are  very 
susceptible for NK and AK cell killing, reveal that the CTL clone and its subciones 
preferentially lysed  B  lymphoma target  cells.  This  autologous and allogeneic 
anti-lymphoma activity was not M HC-restricted and the cytotoxic reaction against 
the lymphoma cells was shown to be inhibited by a monocional antibody directed 
against LFA but not by antibodies against T3 and T4. 
The CTL clone MWS-14 and its subclones were obtained by cocultivating the 
E+ fraction of the PBL from a  B cell lymphoma patient with fresh autologous 
tumor cells, in primary and secondary MLTC followed by limiting dilution of 
the responder cells. Primary stimulation with the MPL cells did not result in the 
induction of cytotoxic activity (Table  I).  Restimulation, however, generated a 
cytotoxic reaction against the MPL cells, indicating that the PBL contained a 
small  number  of clones  that  could  be  enriched  for  cytotoxicity against  the 
stimulator cell by repetitive stimulation. On the other hand, it cannot be excluded 
that suppressor cells present in  tumor-bearing individuals (30,  31) were elimi- 
nated by these culture conditions. 
We have shown previously that PBL of a melanoma patient that failed to kill YSSEL  ET  AL.  249 
autologous short-term cultured melanoma cells, could be activated by cocultiva- 
tion  with  the autologous melanoma  cells,  which  resulted  in  the  generation  of 
cytotoxicity against autologous tumor cells (5).  These CTL clones were shown 
to have a  cytotoxic reactivity predominantly  restricted to (short-term)  cultured 
melanoma cells.  Although  it  was demonstrated  that  the cytotoxic reactivity of 
the anti-melanoma CTL clones was not due to some form of AK activity, it could 
not be ruled out completely that culturing of the melanoma cells contributed in 
some way to the preferential cytotoxic reactivity against these cells. 
However, similar  CTL  clones were obtained  in  the  present  study  in  which 
fresh  noncultured  lymphoma  cells  were  used.  These  B  lymphoma  cells  were 
shown to be insensitive for the activated T  cell bulk cultures and a  CTL clone 
with very high AK activity as measured against K562 cells. Moreover, MPL cells 
were only lysed by CTL clones, specific for those MHC determinants present on 
the  lymphoma  cell  surface  (HLA-A2,  HLA-DRw6, and  HLA-DC-1),  whereas 
CTL clones directed at MHC determinants not present on the MPL cells did not 
lyse these cells. Given the fact that MPL cells appear to be sensitive for specific 
CTL,  it  seems fair  to conclude  that  the  cytotoxic activity of MWS-14 against 
autologous tumor cells is antigen specific. These results confirm and extend our 
previous findings obtained with CTL clones that preferentially lysed melanoma 
cells (5). The nature of the antigen(s) expressed on the tumor cells that are being 
recognized by MWS-14 remains to be determined.  The panel studies show that 
MWS-14 and its subclones killed all B lymphoma target cells as far as tested. In 
contrast,  only 2 or 3 of the  23 control cell lines were killed.  Although a  small 
panel of B lymphomas was tested, these data suggest that MWS-14 recognizes an 
antigen preferentially expressed on malignant B lymphoma cells. Normal autolo- 
gous T  blasts derived from the PBL of the B lymphoma patients were not killed, 
indicating that the target antigen  is expressed only on the malignant  cells. This 
notion  is  also  supported  by the  finding  that  an  EBV-transformed  B  cell  line 
derived from the normal B cells of one donor (KOS) was not killed by MWS-14, 
whereas the  B  lymphoma cells of this donor were lysed efficiently. The deter- 
minant recognized by MWS-14 seems not to be restricted to B lymphoma cells, 
since 2, and 3, out of 23 nonrelated normal and malignant cell lines were killed 
by MWS-14-30 and MWS-14-34, respectively. The nature of this reactivity has 
to be investigated but it must be noted that  the target  cells killed by MWS-14 
subclones (HPB-ALL, T24, and CEM) are occasionally also killed by CTL clones 
with well-defined allospecificities (reference 32; H. Spits, unpublished), especially 
when  such  ailospecific  CTL  clones are  in  culture  for a  long  period  of time. 
Similar results have been reported by Brooks et al. (20), who showed that mouse 
allospecific CTL clones acquire natural killer cell-like activities after long periods 
of culture. Thus, the activity of MWS-14-30 against T24 and HPB-ALL and of 
MWS-14-34 against HPB-ALL, T24, and CEM may be due to acquired nonspe- 
cific killing activity. 
In many immunological systems of both mouse and man, CTL activity against 
autologous  target  cells,  in  particular  virus-infected  autologous  cells,  has  been 
demonstrated, and involves the recognition of the antigens in the context of self 
MHC  determinants  (33-36).  HLA-restricted  cytotoxicity  can  be  blocked  by 
monoclonal  antibodies  against  MHC  products  (6,  7).  The  panel  study  that 250  CYTOTOXIC  T  LYMPHOCYTE  CLONES  AGAINST  HUMAN  LYMPHOMA 
demonstrated that  MWS-14-killed B  lymphoma cells, irrespective of the HLA 
phenotype of these cells, already indicated that the activity of MWS-14  is not 
restricted by polymorphic HLA determinants. This notion was supported by the 
finding that monoclonal antibodies, directed against monomorphic determinants 
present on class I and class II MHC antigens (which inhibited very efficiently the 
activity of aliospecific CTL clones against MPL cells), failed to inhibit the activity 
of MWS-14 and MWS-14-34 against the MPL cells. In addition, the results of 
the blocking experiments made it unlikely that MWS-14 recognizes "alien" MHC 
antigens, which can be expressed on malignant cells (37-39).  Our CTL clones 
differ from the  lymphokine-activated killer (LAK) cells recently described by 
Grimm et at.  (40,  41).  Although these LAK also were capable of lysing NK- 
resistant fresh human tumor cells, they demonstrated a much broader specificity. 
In  addition,  these  cells  were  all  of  the  T8+  phenotype,  whereas  the  anti° 
lymphoma CTL clones are T4+. However, the most important difference is that 
the anti-tumor cell reactivity of the LAK cells was established with bulk cultures, 
which allows no exact comparison with the CTL clones described here. 
It has recently been shown that the T  cell receptor for alloantigen is associated 
with T3 (28). Moreover a T3-positive NK clone has been shown to have a T  cell 
receptor for non-MHC  determinants present on  K562  cells that  is  associated 
with T3 (42). However, the blocking studies using monoclonal antibodies against 
T3  (7,  26)  and  the  modulation  experiments  with  anti-T3  (Fig.  1)  failed  to 
demonstrate any involvement of T3 in the cytotoxic activity of MWS-14 against 
the  MPL  cells.  These  results are  similar to  those obtained  in  the  melanoma 
system, in which it was demonstrated that T3 was not involved in the preferential 
cytotoxic activity of CTL clones against autologous melanoma cells (5). The data 
presented  here  and  in  the  previous  paper  (5)  indicate  that  a  novel  type  of 
cytotoxic activity, which is antigen specific, but not associated with T3, can be 
generated in vitro. 
Monoclonal antibodies to the T4 glycoprotein have been shown to be able to 
block the cytotoxic activity of T4+ CTL (26, 27).  In spite of the expression of 
T4  on  CTL clone MWS-14,  blocking studies with anti-T4  reagents indicated 
that T4 is not involved in the cytotoxic activity of this clone against MPL. This 
is  not  surprising  because T4  seems to  play a  role  in  class  II  MHC-restricted 
cytotoxic reactions only, and the involvement of class  II MHC antigens in  the 
activity  of  MWS-14  against  MPL  could  not  be  demonstrated.  It  has  been 
hypothesized that the T4 structure might serve as a stabilizer of the adhesion of 
the CTL to the target cell in the case of T4+ CTL with a low affinity for their 
target antigen (26, 43). Therefore, the failure of OKT-4A to block the cytotoxic 
reaction of MWS-14 against MPL might also be explained by assuming that this 
clone has a high affinity for the autologous B lymphoma cells. 
LFA-1 is thought to represent an adhesion structure that is important for cell- 
cell contact (16). Antibodies against LFA-1 block antigen-specific (2, 17, 29), NK 
(12,  29), AK (12),  K cell activity (F.  Miedema, submitted for publication), and 
lectin-dependent cytotoxicity (12).  By preventing conjugate formation between 
the effector and target cells (H. Spits and R. Roozemond, unpublished observa- 
tions). It is shown (Table VI) that LFA-1, as defined by the monoclonal antibodies 
SPV-L1 and SPV-L5, also plays a role in the auto-tumor CTL activity of MWS- YSSEL ET  AL.  251 
14,  indicating that cell-cell contact is indeed required  for the cytotoxicity me- 
diated by clone MWS-14 to occur. 
Experiments to investigate the nature of the antigen on the B lymphoma cells 
recognized by the CTL clones are currently in progress. 
Summary 
A  human  cytotoxic T  cell  clone  (MWS-14)  with  auto-tumor  reactivity was 
established in  serum-free medium  in a  mixed tumor cell culture by repetitive 
stimulation with fresh autologous lymphoma cells. This clone and its subclones 
are  of the  T3+  T4+  T8-  phenotype.  They  were  strongly  cytotoxic  for  the 
autologous  lymphoma cells,  whereas  autologous  PHA  blasts  were  not  killed. 
Analysis of the specificity of MWS-14,  MWS-14-30,  and MWS-14-34  indicated 
that these CTL clones were cytotoxic for 7/7 aliogeneic iymphoma cells, whereas 
only 3/23 of normal and non-lymphoma cells were lysed. Blocking studies with 
monoclonal antibodies directed at MHC class I and class II antigens showed that 
this  preferential,  anti-lymphoma reactivity was  not directed  at  HLA determi- 
nants. The anti-lymphoma activity is not due to an aspecific susceptibility of the 
lymphoma cells to  lysis.  In contrast  to  CTL clones specific for  HLA antigens 
present on the lymphoma cells, T3  and T4 were not involved in the cytotoxic 
reaction of MWS-14 against the autologous lymphoma cells.  The reactivity of 
this  clone  could  be  blocked  by  a  monoclonal  antibody directed  at  leukocyte 
function-associated antigen. 
It can be concluded from these results that these T4+ CTL clones recognize 
a  determinant, which is  preferentially expressed  on autologous and allogeneic 
lymphoma cells. 
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